SmartCells, Inc
Umbilical cord blood stem cell collection, processing, and cryogenic storage service
- Sector
- Biotech
- Headquarters
- BEVERLY, MA
- Latest Form D
- $1.7M, Mar 2010
- Total capital
- $11.2M
- Federal grants
- $8.3M
- 12 awards · 2004–2009
- 12× sector median 1 award
- Private capital raised
- $2.9M
- 2 Form D · last Mar 2010
- 199 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 8
- 20 pending · first 2015
- Rank in peer group#1 of 12
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$1.7M
- Federal grantHealth and Human S · Phase II · SmartInsulin ADME and IND-enabling Preclinical Studies$1.6M
- Federal grantHealth and Human S · Phase II · SmartInsulin ADME and IND-enabling Preclinical Studies$337K
- Private capital raisedForm D · SEC · 1st filing$1.1M
- Federal grantHealth and Human S · Phase II · SmartInsulin Stability, Process Development, Assay Validation and GMP Manufacturi$851K
- Federal grantHealth and Human S · Phase II · SmartInsulin Stability, Process Development, Assay Validation and GMP Manufacturi$1.5M
- Federal grantHealth and Human S · Phase II · SmartInsulin ADME and IND-enabling Preclinical Studies$1.1M
Show 7 earlier federal awards
- Federal grantHealth and Human S · Phase II · SmartInsulin Stability, Process Development, Assay Validation and GMP Manufacturi$284K
- Federal grantHealth and Human S · Phase I · Multimeric RNA Aptamers for Glucose-Responsive Insulin Formulations$335K
- Federal grantHealth and Human S · Phase I · Multimeric RNA Aptamers for Glucose-Responsive Insulin Formulations$394K
- Federal grantHealth and Human S · Phase I · RNA-Biopolymer Nanostructures for Smart Insulin Delivery$195K
- Federal grantHealth and Human S · Phase II · Safety Profile Optimization of Glucose-Regulated Insulin Formulations$750K
- Federal grantHealth and Human S · Phase I · Glucose-Responsive Self-Regulated Insulin Delivery$438K
- Federal grantHealth and Human S · Phase I · Glucose-Responsive Self-Regulated Insulin Delivery$482K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
58months
from SmartCells, Inc’s first federal award to its first private round.
- First federal award · Sep 2004
- Health and Human S · $482K
- First Form D · Jul 2009
- $1.1M · 1st Form D
- Awards before first raise
- 10 awards
An association in public records, not a cause or a prediction.
Standing among 12 peers
Line = medianBiotech · Service
- Granted patents#1 · top 8%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Todd ZionResearcherDirectorLinked by 6 patents · $8.3M in grants as PI
- Edward CannonDirectorNamed in SEC Form D filings
- Henry KayDirectorNamed in SEC Form D filings
- James HerrimanExecutive OfficerNamed in SEC Form D filings
- Robert ManningDirectorNamed in SEC Form D filings
What it has protected
USPTO · 8 granted of 28- GrantedConjugate Based Systems For Controlled Insulin DeliveryUSPTOUS 11,413,352
- GrantedConjugate Based Systems For Controlled Drug DeliveryUSPTOUS 10,398,781
- GrantedBinding-site Modified Lectins And Uses ThereofUSPTOUS 9,745,355
Show all 28 patent records
- Conjugate Based Systems For Controlled Insulin DeliveryAug 16, 2022 · US 11,413,352Granted
- Conjugate Based Systems For Controlled Drug DeliverySep 3, 2019 · US 10,398,781Granted
- Binding-site Modified Lectins And Uses ThereofAug 29, 2017 · US 9,745,355Granted
- Conjugate Based Systems For Controlled Drug DeliveryFeb 28, 2017 · US 9,579,391Granted
- Crystalline Insulin-conjugatesJan 26, 2017 · Application 15288362Pending
- Crystalline Insulin-conjugatesOct 11, 2016 · US 9,463,249Granted
- Conjugate Based Systems For Controlled Drug DeliveryJul 7, 2016 · Application 15040004Pending
- Conjugate Based Systems For Controlled Drug DeliveryFeb 23, 2016 · US 9,265,838Granted
- Exogenously Triggered Controlled Release Materials And Uses ThereofAug 25, 2015 · US 9,114,176Granted
- Terminally-functionalized Conjugates And Uses ThereofAug 4, 2015 · US 9,095,623Granted
- Soluble Non-depot Insulin Conjugates And Uses ThereofFeb 6, 2014 · Application 14055911Pending
- Conjugate Based Systems For Controlled Drug DeliveryApplication PCTUS2010022268Pending
- Soluble Non-depot Insulin Conjugates And Uses ThereofApplication PCTUS2010022272Pending
- Crystalline Insulin-conjugatesApplication PCTUS2010022277Pending
- Synthetic Conjugates And Uses ThereofApplication PCTUS2010022256Pending
- Exogenously Triggered Controlled Release Materials And Uses ThereofApplication PCTUS2010022225Pending
- Methods For Reducing The Mitogenicity Of Lectin CompositionsApplication PCTUS2006041167Pending
- Polymer-drug ConjugatesApplication PCTUS2006041035Pending
- Conjugate Based Systems For Controlled Insulin DeliveryApplication PCTUS2018065321Pending
- Conjugate Based Systems For Controlled Insulin DeliveryApplication 62625491Pending
- Uses Of Macrophage Mannose Receptor To Screen Compounds And Uses Of These CompoundsApplication PCTUS2011053390Pending
- Recombinant Lectins, Binding-site Modified Lectins And Uses ThereofApplication PCTUS2011044989Pending
- Drug-ligand Conjugates, Synthesis Thereof, And Intermediates TheretoApplication PCTUS2011044961Pending
- Recombinantly Expressed Insulin Polypeptides And Uses ThereofApplication PCTUS2011045008Pending
- Drug-ligand Conjugates, Synthesis Thereof, And Intermediates TheretoApplication PCTUS2011044936Pending
- Polynucleotide Aptamer-based Cross -linked Materials And Uses ThereofApplication PCTUS2010022237Pending
- Terminally-functionalized Conjugates And Uses ThereofApplication PCTUS2010022251Pending
- Binding-site Modified Lectins And Uses ThereofApplication PCTUS2010022213Pending
Related companies, and why
- LABGENIUS LtdSimilar federal contract value in Biotech · null in contracts
- OmniAb, Inc.Similar federal contract value in Biotech · null in contracts
- DepYmed Inc.Similar federal contract value in Biotech · null in contracts
- Halodine LLCSimilar federal contract value in Biotech · null in contracts
- Osmol TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Gennao BioSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .